Novartis Keeps Grip On Eye Drug Patent In Fed. Circ.

Law360, New York (August 8, 2012, 7:06 PM EDT) -- The Federal Circuit on Wednesday affirmed the validity of a portion of Novartis AG's patent for popular eye allergy treatment Patanol, leaving intact a lower judge's ruling that barred Apotex Inc. from selling its generic challenger.

Though the appeals court said that most of Novartis-unit Alcon Inc.'s patent was invalid because it had been predicted by a 1995 scientific study, it said the study didn't describe two of patent's eight infringed claims, meaning they were valid.

The decision means that U.S. District Judge Richard L. Young's...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.